{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T15:36:27Z","timestamp":1771947387382,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007052","name":"Memorial Sloan Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Kidney Disease and Health"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1053\/j.akdh.2024.10.005","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T13:10:15Z","timestamp":1743599415000},"page":"69-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Onconephrology"],"prefix":"10.1053","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-9680","authenticated-orcid":false,"given":"Sheron","family":"Latcha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Victoria","family":"Gutgarts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belen Nunez","family":"Cespedes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1225-0370","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib1","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41581-018-0077-4","article-title":"The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group","volume":"15","author":"Leung","year":"2019","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib2","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1681\/ASN.2015020185","article-title":"Light chain proximal tubulopathy: clinical and pathologic characteristics in the modern treatment era. Journal of the American society of nephrology","volume":"27","author":"Stokes","year":"2016","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.akdh.2024.10.005_bib3","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.ajkd.2021.04.015","article-title":"Kidney transplantation in patients with monoclonal gammopathy of renal significance (MGRS)-Associated lesions: a case series","volume":"79","author":"Heybeli","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"11","key":"10.1053\/j.akdh.2024.10.005_bib4","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.akdh.2024.10.005_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1053\/j.akdh.2024.10.005_bib6","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/sj.ki.5001990","article-title":"Immunofluorescence on pronase-digested paraffin sections: a valuable salvage technique for renal biopsies","volume":"70","author":"Nasr","year":"2006","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.nefro.2020.11.015","article-title":"Monoclonal gammopathy of renal significance: early diagnosis is key","volume":"41","author":"Alonso-Titos","year":"2021","journal-title":"Nefrologia"},{"issue":"22","key":"10.1053\/j.akdh.2024.10.005_bib8","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1182\/blood.2019004460","article-title":"Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA","volume":"136","author":"Palladini","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/bjh.17052","article-title":"Daratumumab-based therapy for patients with monoclonal gammopathy of renal significance","volume":"193","author":"Kastritis","year":"2021","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.akdh.2024.10.005_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.ackd.2021.11.003","article-title":"Kidney disease following hematopoietic stem cell transplantation","volume":"29","author":"Abudayyeh","year":"2022","journal-title":"Adv Chronic Kidney Dis"},{"issue":"14","key":"10.1053\/j.akdh.2024.10.005_bib12","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","article-title":"Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA","volume":"139","author":"Cavo","year":"2022","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.akdh.2024.10.005_bib14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1200\/JCO.18.02096","article-title":"Treatment of multiple myeloma: ASCO and CCO joint clinical practice guideline","volume":"37","author":"Mikhael","year":"2019","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.akdh.2024.10.005_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1053\/j.akdh.2024.10.005_bib16","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"\u201d1031Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events\u201d","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib17","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI? PRO","volume":"3","author":"Herrmann","year":"2021","journal-title":"Kidney360"},{"key":"10.1053\/j.akdh.2024.10.005_bib18","author":"Sprangers"},{"key":"10.1053\/j.akdh.2024.10.005_bib20","series-title":"Center For International Blood and Marrow Transplant Research. HCT Summary Slide","year":"2023"},{"issue":"23","key":"10.1053\/j.akdh.2024.10.005_bib21","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal complications of hematopoietic-cell transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib22","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1093\/ckj\/sfad023","article-title":"Glomerular diseases post-hematopoietic stem cell transplantation: pathologic spectrum and plausible mechanisms","volume":"16","author":"Caza","year":"2023","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib23","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1093\/ckj\/sfac264","article-title":"Clinico-pathological correlations and outcomes of de novo glomerular diseases in patients after haematopoietic stem cell transplantation","volume":"16","author":"Yap","year":"2022","journal-title":"Clin Kidney J"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000046273","article-title":"Membranous glomerulopathy associated with graft-versus-host disease following allogeneic stem cell transplantation : report of 2 cases and review of the literature","volume":"21","author":"Lin","year":"2001","journal-title":"Am J Nephrol"},{"key":"10.1053\/j.akdh.2024.10.005_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.humpath.2015.12.005","article-title":"Clinicopathological analysis of allogeneic hematopoietic stem cell transplantation\u2013related membranous glomerulonephritis","volume":"50","author":"Hiramatsu","year":"2016","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2141.2005.05728.x","article-title":"Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation","volume":"131","author":"Srinivasan","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1053\/j.akdh.2024.10.005_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/ejh.12149","article-title":"Chronic graft-versus-host disease of the kidney in patients with allogenic hematopoietic stem cell transplant","volume":"91","author":"Fraile","year":"2013","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib28","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1399-0012.2004.00294.x","article-title":"Nephrotic syndrome after stem cell transplantation","volume":"19","author":"Stevenson","year":"2005","journal-title":"Clin Transplant"},{"issue":"4","key":"10.1053\/j.akdh.2024.10.005_bib29","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2215\/CJN.00380705","article-title":"Nephrotic syndrome after hematopoietic cell transplantation: do glomerular lesions represent renal graft-versus-host disease?","volume":"1","author":"Brukamp","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib30","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1681\/ASN.2021111488","article-title":"Hematopoietic stem cell transplant-membranous nephropathy is associated with protocadherin FAT1","volume":"33","author":"Sethi","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.akdh.2024.10.005_bib31","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1016\/j.ekir.2021.04.033","article-title":"NELL1-Associated membranous glomerulopathy after hematopoietic stem cell transplantation","volume":"6","author":"Kudose","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib32","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/imj.13098","article-title":"Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation","volume":"46","author":"Wong","year":"2016","journal-title":"Intern Med J"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib33","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/1871525711311010011","article-title":"The management of membranous glomerulopathy in allogeneic stem cells transplantation: updated literature","volume":"11","author":"Niscola","year":"2013","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"issue":"3","key":"10.1053\/j.akdh.2024.10.005_bib34","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/sj.ki.5000055","article-title":"Acute renal failure in hematopoietic cell transplantation","volume":"69","author":"Parikh","year":"2006","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.akdh.2024.10.005_bib35","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.bbmt.2018.10.015","article-title":"Transplant-associated thrombotic microangiopathy is a multifactorial disease unresponsive to immunosuppressant withdrawal","volume":"25","author":"Li","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1053\/j.akdh.2024.10.005_bib36","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/ph15070845","article-title":"Complement system as a new target for hematopoietic stem cell transplantation-related thrombotic microangiopathy","volume":"15","author":"Ardissino","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1053\/j.akdh.2024.10.005_bib37","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/bmt.2016.343","article-title":"Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants","volume":"52","author":"Glezerman","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 2","key":"10.1053\/j.akdh.2024.10.005_bib38","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.2215\/CJN.02770707","article-title":"BK virus nephritis after renal transplantation","volume":"3","author":"Dall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.akdh.2024.10.005_bib39","doi-asserted-by":"crossref","first-page":"409","DOI":"10.34067\/KID.0000000000000061","article-title":"Chemotherapy-associated thrombotic microangiopathy","volume":"4","author":"Aklilu Abinet","year":"2023","journal-title":"Kidney360"},{"issue":"7","key":"10.1053\/j.akdh.2024.10.005_bib40","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.akdh.2024.10.005_bib41","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/MD.0b013e3182603598","article-title":"Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases","volume":"91","author":"Lechner","year":"2012","journal-title":"Medicine"},{"issue":"2","key":"10.1053\/j.akdh.2024.10.005_bib42","doi-asserted-by":"crossref","first-page":"130","DOI":"10.5414\/CNP71130","article-title":"Gemcitabine nephrotoxicity and hemolytic uremic syndrome: report of 29 cases from a single institution","volume":"71","author":"Glezerman","year":"2009","journal-title":"Clin Nephrol"},{"issue":"11","key":"10.1053\/j.akdh.2024.10.005_bib43","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1093\/ndt\/gfl507","article-title":"Gemcitabine-induced thrombotic microangiopathy: a systematic review","volume":"21","author":"Hassane","year":"2006","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.akdh.2024.10.005_bib44","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s00277-004-0938-8","article-title":"Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution","volume":"84","author":"M\u00fcller","year":"2005","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12882-021-02386-y","article-title":"\"Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report\"","volume":"22","author":"Nishikubo","year":"2021","journal-title":"BMC Nephrol"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF00873232","article-title":"Phase II trial of gemcitabine (2, 2\u2032-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas","volume":"12","author":"Casper","year":"1994","journal-title":"Invest N Drugs"},{"issue":"3","key":"10.1053\/j.akdh.2024.10.005_bib47","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"\"Guidelines on the use of therapeutic apheresis in clinical practice\u2013evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue\"","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J Clin Apher"},{"issue":"1","key":"10.1053\/j.akdh.2024.10.005_bib48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12882-018-0812-x","article-title":"\u201cThe use of eculizumab in gemcitabine induced thrombotic microangiopathy\u201d","volume":"19","author":"Krishnappa","year":"2018","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1053\/j.akdh.2024.10.005_bib49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.revmed.2015.12.027","article-title":"\"Clinical efficacy of eculizumab as treatment of gemcitabine-induced thrombotic microangiopathy: a case report\"","volume":"37","author":"Rogier","year":"2016","journal-title":"Rev Med Interne"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib50","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1053\/j.ajkd.2018.06.013","article-title":"Emerging concepts in hematopoietic stem cell transplantation-associated renal thrombotic microangiopathy and prospects for new treatments","volume":"72","author":"Wanchoo","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.akdh.2024.10.005_bib51","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.thromres.2023.02.012","article-title":"Eculizumab in the management of drug-induced thrombotic microangiopathy: a scoping review of the literature","volume":"224","author":"Zafar","year":"2023","journal-title":"Thromb Res"},{"issue":"6","key":"10.1053\/j.akdh.2024.10.005_bib52","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.21037\/jgo-22-509","article-title":"Gemcitabine-induced thrombotic microangiopathy treated with eculizumab: a case report","volume":"13","author":"Van den Eeckhaut","year":"2022","journal-title":"J Gastrointest Oncol"}],"container-title":["Advances in Kidney Disease and Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949813924001575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T01:20:53Z","timestamp":1745025653000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949813924001575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2949813924001575"],"URL":"https:\/\/doi.org\/10.1053\/j.akdh.2024.10.005","relation":{},"ISSN":["2949-8139"],"issn-type":[{"value":"2949-8139","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Onconephrology","name":"articletitle","label":"Article Title"},{"value":"Advances in Kidney Disease and Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.akdh.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the National Kidney Foundation, Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}